Making a difference in rheumatoid arthritis
Rheumatoid arthritis is a disease affecting more than 21 million people worldwide and around one per cent of the population in the UK and Ireland (Source: Arthritis Research UK).
Until just a few decades ago, people with rheumatoid arthritis had to resign themselves to a distressing loss of quality of life, with constant pain and an increasing loss of mobility as the disease progressed.
Roche’s commitment to understanding the causes and mechanisms of rheumatoid arthritis has contributed towards revolutionising treatment. Today, new biopharmaceutical therapies have made significant progress by effectively treating this disease and inhibiting joint damage and pain. The tools we are developing for quick diagnosis may also permit much earlier treatment in the future.
The exact cause of rheumatoid arthritis is still unknown, and as yet there is no cure, but our research continues and remission, where the disease goes into long-term hibernation, has become a realistic objective.
We have a rich history of medical innovation in this field and a promising future with our focus on personalised healthcare - an approach that specifically takes into account emerging knowledge about the molecular pathology of diseases and people’s individual characteristics.